BioNTech: COVID-19 vaccine co-developed with Pfizer showing strong immune response in early trial
|Biopharmaceutical New Technologies (BioNTech) announced on Wednesday that the COVID-19 vaccine that they co-developed with Pfizer triggered a strong immune response in the early stage of human trials.
Additional takeaways
"Planning to test most promising of four vaccines on up to 30,000 healthy participants in the US and Europe."
"Planning to manufacture up to 100 million doses by the end of 2020 if regulators give the green light."
"Will also make at least another 1.2 billion doses by the end of 2021 in Germany and the US."
Market reaction
This headline seems to be providing a boost to market sentiment and helping major European equity indexes recover from daily lows. As of writing, Germany's DAX 30 was down 0.42% on the day at 12,260 points.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.